丽珠肠乐治疗慢性肝炎和肝硬化的临床疗效观察

Observations on the therapeutic efficacy of Li-Zhu-Chang-Le in the treatment of chronic hepatitis

应用常规保肝治疗和加用丽珠肠乐两组(对照组和治疗组)共治疗120例。治疗组和对照组比较,结果如下:临床症状总有效率在慢迁肝、慢活肝及肝硬化中P值均<0.01。慢迁肝中ALT复常中P<0.05,肝硬化中ALT下降、SB下降、白蛋白上升及鲎血试验中转阴P值分别为<0.01、<0.01、<0.05和<0.01。本文提示在慢性肝炎、肝硬化常规保肝治疗基础上再加用丽珠肠乐能取得较好疗效,值得推广应用。

Twenty four patients received either conventional liver protecting medicines or Li-Zhu-Chang-Le treatment (control and treatment groups, 12 patients each). In comparison, the differences in therapeutic results between the 2 groups were:1. The difference in overall symptomatic improvement in patients with chronic persistent hepatitis and chronic active hepatitis is significant, with a P value of<0.01.2. In patients with cirrhosis, the differences in lowering SB, elevation of albumin, normalization of ALT and negative reversal of limulus lysolate test are all significant, with P values of<0.01, <0.01, <0.05 and<0.01 respectively.3. The difference in normalization of ALT in patients with chronic persistent hepatitis is significant, with a P value of, 0.05.The results suggest that in treating chronic hepatitis, addition of Li-Zhu-Chang-Le to conventional liver protecting medicines will achieve a better therapeutic effect.